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NRELATED ADULT CORD BLOOD TRANSPLANTS FOR ADULTS WITH
CUTE LEUKEMIA: COMPARISON WITH OTHER STEM CELL SOURCES
luckman, E. Eurocord, Hospital Saint Louis, Paris, France
Unrelated cord blood transplant is an option for adults who lack
n HLA identical bone marrow donor. Eurocord has analyzed
esults in 171 patients with malignancies and compared with HLA
dentical unrelated bone marrow transplant or to haploidentical
eripheral blood related transplants.
Results in adults: One-hundred and seventy one patients were
ransplanted after 1997. Median age was 29 years (15-55), and
edian follow-up time was 18 months (1-71). Most patients had
cute or chronic leukemia (n  142, 83%), 91 (53%) were trans-
lanted in advanced phase and 32 (19%) had failed an autologous
ransplant. Most patients (87%) received an HLA incompatible CB
nit with 1-2 HLA mismatches. At infusion, the median number of
ucleated cells (NC) and CD34 cells was 2.1  107/kg and 1 
05/kg, respectively. The cumulative incidence (CI) of neutrophil
ecovery at day 60 was 72  3% with a median of 28 days (11-57).
higher NC and use of hematopoietic growth factors were inde-
endently associated with faster neutrophil recovery. The CI of
rade II-IV acute-GVHD was 32  4% and it was not associated
ith the number of HLA mismatches. The 2-year CI of chronic-
VHD, transplant-related-mortality and relapse were 36  10%,
1  4% and 22  4%, respectively. At 2-years, disease-free-
urvival (DFS) for patients transplanted in early, intermediate and
dvanced phase of disease was 41  9%, 34  10% and 18  4%,
espectively. In multivariate analyses, advanced status of the disease
as an adverse factor for relapse and DFS.
Comparison with HLA identical unrelated bone marrow
ransplants: Eurocord and EBMT have performed a matched pair
nalysis to compare the results of UCB and BMT from unrelated
onors in adults with acute leukemia. Eighty-one patients receiving
nrelated donor UCB (90% HLA-mismatched) were matched for
ge, diagnosis, status of disease at transplant and use of total body
rradiation and compared with 162 recipients of unmanipulated
LA-matched unrelated donor BM. Neutrophil recovery was de-
ayed in recipients of UCB and incidence of acute GVHD  grade
I was higher in those receiving BM. The 2-year cumulative inci-
ence of chronic GVHD, TRM, leukemia relapse, 2-year proba-
ility of survival and leukemia-free survival were not signiﬁcantly
ifferent.
Comparison with haploidentical related peripheral blood
ransplant: We have compared the outcome in 229 patients re-
eiving a haplo mismatched related transplant to 139 patients who
eceived a mismatched unrelated cord blood transplant. There
ere 220 AML and 148 ALL which were analyzed separately. In
ML, engraftment was faster in patients with haplo transplant.
here was more GVH in the UCBT group (23 vs 5%). Transplant
elated mortality (58 vs 46%) and rate of relapse (24 vs 18%) were
ot different. Leukemia free survival was identical (30 vs 24%). In
LL engraftment and GVH rates were similar to the AML pa-
ients, TRM was identical after haplo or CB. LFS was higher in CB
han in haplo (36 vs 13%). The difference was more signiﬁcant in
atients transplanted in CR2 or more advanced disease.
Conclusion: UCBT is a clear alternative for adults with he-
atological malignancies lacking an HLA-matched related or
nrelated donor. These data suggest that, despite increased
LA disparity, UCB from unrelated donors offers comparable
esults to matched unrelated BM in adults with acute leukemia,
eading to the conclusion that the donor search process for BM
nd UCB from unrelated donors should be started simulta-
eously in adults, especially in patients with acute leukemia
here the time factor is very important. The choice of units
ontaining a higher NC and a policy of earlier transplantation
re likely to provide better results.
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ORD BLOOD TRANSPLANTATION TO ADULT PATIENTS: A NEW YORK
LOOD CENTER UPDATE
ubinstein, P. Stevens, C.E., Scaradavou, A. National Cord Blood
rogram–New York Blood Center, New York, NY
Since 1993, the National Cord Blood Program has provided cord
lood transplants to 1750 recipients worldwide, of whom 396 16
ears old (22.6%). Of the adults, 65% were 25 years old, 90%
ad hematologic malignancies, 33% had advanced disease (IBMTR
lassiﬁcation), 13% had received a prior auto or allograft and 11%
eceived double-unit transplants. Of single-unit transplant recipi-
nts, 22% had 1, 66% had 2 and 10% had 3 HLA mismatches
HLA-A and -B at serological resolution level, DRB1 at the allele
evel). TNC doses were below 5  107 in all but 5 patients.
ngraftment was associated with TNC dose (P  0.004) and
LA-matching (p  0.003), especially when recipients of mis-
atched only in the GvH direction were counted as matched (p 
.001). Signiﬁcant differences in the probability of engraftment
ere also related to the conditioning regimens and to the use of
ouble unit transplantation. Acute GvHD grade III–IV developed
n 25% of cases, and was lower (10%) in cases without HLA
ismatches in the GvHD direction. This was not signiﬁcant in this
ample, however. The probability of relapse was 15% and was
ower in cases with lower IBMTR risk factors (NS in this sample).
ithin the adult group (age  16-67), age at transplantation was
ot signiﬁcantly related to the probability of survival at 1 or 5
ears. The difference in 1 year survival between recipients of grafts
ith  and grafts with 2.5  107 was not signiﬁcant (28% vs.
4%). The absence of HLA rejection mismatches was signiﬁcantly
ssociated: with survival at 1 year (survival  68% vs. 27%, P 
.005). Overall survival was 23% at 5 years. Engraftment and
urvival were signiﬁcantly better in a group of 45 patients given a
wo-unit transplant, the majority of which also were treated with
udarabine-containing regimens. These results extend the data on
dult recipients of cord blood grafts beyond those previously reported.
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ORD BLOOD TRANSPLANTS FOR ADULTS USING MYELOABLATIVE
ONDITIONING
akahashi, S. Division of Molecular Therapy, The Institute of Medical
cience, The University of Tokyo, Tokyo, Japan
Cord blood transplantation (CBT) from unrelated donors has
omparable efﬁcacy to bone marrow transplantation (BMT) from
nrelated donors and can restore hematopoiesis with acceptable
oxicities in adults. We studied the clinical outcomes of 92 adult
atients with hematological malignancies who received CBT from
nrelated donors after myeloablative conditioning. Overall rate of
igh-risk patients was 58% and median follow-up was 22 months
range: 1 to 82 months). Three patients died within 28 days of
BT and primary graft failure occurred in 3 of 89 evaluable
ecipients. A median time of neutrophil (500/L) and platelet (
0,000/L) engraftment were 22 and 40 days. The cumulative
ncidence of grades II to IV and grades III and IV acute GVHD
ere 52% and 8%. The number of patients suffered from any
ype of chronic GVHD was 67 of 73 evaluable recipients (92%).
wenty-two was extensive type (30%). Despite using human leu-
ocyte antigen (HLA)-mismatched cord blood graft in all cases,
apid tapering of immunosuppressants after transplantation and
he low incidence to treat severe acute GVHD with steroid,
VHD-related death was only 2 of all 23 deaths (9%). The 1-year
robability of transplant-related mortality (TRM) was 20% and
he 2-year probability of relapse was 18%. The 2-year probabilities
f disease-free survival (DFS) were 95% in standard-risk patients
N  39) and 60% in high-risk patients (N  53). We speculated
hat the immune reconstitution process over a period of several
onths after CBT might have contributed to those promisinglinical results. Circulating T cell counts normalized after 3
onths for CD8 and 4 months for CD4 in our CBT recipients,
